Johnson & Johnson $JNJ Stake Lowered by Pinnacle Associates Ltd.

Pinnacle Associates Ltd. reduced its position in Johnson & Johnson (NYSE:JNJ) by 17.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,659,970 shares of the company’s stock after selling 345,156 shares during the quarter. Johnson & Johnson accounts for approximately 4.1% of Pinnacle Associates Ltd.’s investment portfolio, making the stock its 2nd largest holding. Pinnacle Associates Ltd. owned approximately 0.07% of Johnson & Johnson worth $307,792,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Abich Financial Wealth Management LLC bought a new stake in shares of Johnson & Johnson in the 3rd quarter valued at about $26,000. Evolution Wealth Management Inc. bought a new position in shares of Johnson & Johnson during the second quarter valued at approximately $27,000. Clayton Financial Group LLC purchased a new position in Johnson & Johnson during the third quarter valued at approximately $28,000. Semmax Financial Advisors Inc. raised its stake in Johnson & Johnson by 55.0% in the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after buying an additional 72 shares in the last quarter. Finally, Compass Financial Services Inc lifted its holdings in Johnson & Johnson by 707.1% during the third quarter. Compass Financial Services Inc now owns 226 shares of the company’s stock worth $42,000 after buying an additional 198 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Stock Up 0.4%

Shares of JNJ stock opened at $240.57 on Friday. The stock’s fifty day moving average price is $228.36 and its 200 day moving average price is $204.19. Johnson & Johnson has a 1-year low of $141.50 and a 1-year high of $251.71. The company has a market cap of $579.75 billion, a price-to-earnings ratio of 21.77, a price-to-earnings-growth ratio of 2.37 and a beta of 0.34. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.03 and a quick ratio of 0.77.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Saturday, January 31st. The company reported $2.46 EPS for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%.The company had revenue of $24.28 billion during the quarter. On average, research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be issued a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.2%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 47.06%.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Timothy Schmid sold 1,322 shares of the business’s stock in a transaction dated Friday, February 20th. The stock was sold at an average price of $245.66, for a total transaction of $324,762.52. Following the sale, the executive vice president owned 25,447 shares in the company, valued at approximately $6,251,310.02. The trade was a 4.94% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Vanessa Broadhurst sold 6,197 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total value of $1,508,287.83. Following the completion of the transaction, the executive vice president owned 23,003 shares of the company’s stock, valued at approximately $5,598,700.17. The trade was a 21.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 30,142 shares of company stock worth $7,360,528 over the last three months. Corporate insiders own 0.16% of the company’s stock.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA approval of TECVAYLI® plus DARZALEX FASPRO® for relapsed/refractory multiple myeloma — approval was based on strong Phase 3 results showing significant improvements in progression‑free and overall survival, and J&J positions the combo as a potential new standard of care as early as second line. This materially expands the company’s oncology commercial opportunity and is the main catalyst lifting sentiment. PR Newswire: J&J FDA approval
• Positive Sentiment: Inclusion in dividend lists / dividend‑aristocrat coverage — recent articles cite JNJ among Dividend Kings/Aristocrats, reinforcing its appeal to income and defensive investors given decades of payout growth. That supports demand from dividend‑focused funds and conservative investors. 24/7 Wall St.: Dividend Kings
• Neutral Sentiment: JPMorgan raised its price target from $225 to $250 but kept a “neutral” rating — the PT lift signals modest analyst upside recognition of recent catalysts, though the unchanged rating tempers near‑term conviction. Benzinga: JPMorgan price target
• Neutral Sentiment: Direct‑to‑consumer website launch — J&J rolled out a site to sell certain drugs directly to U.S. patients who are uninsured or pay out‑of‑pocket; potential to improve access and margin over time, but impact on revenue is unclear near term. Reuters: direct-to-consumer site
• Negative Sentiment: $65 million Tracleer antitrust settlement — two J&J units agreed to pay $65M to resolve a class action alleging overcharges for the pulmonary hypertension drug; materiality is modest relative to J&J’s scale but it is a headline legal expense. Reuters: Tracleer settlement
• Negative Sentiment: Near‑term price volatility / recent pullback — a few market reports noted a day‑over‑day decline ahead of the approval news; investors should be prepared for swings as the market digests launch timing, uptake and reimbursement dynamics. Zacks: recent decline

Wall Street Analyst Weigh In

JNJ has been the topic of a number of analyst reports. Citigroup lifted their price target on Johnson & Johnson from $232.00 to $250.00 and gave the company a “buy” rating in a report on Thursday, January 22nd. Morgan Stanley set a $262.00 price objective on Johnson & Johnson and gave the company an “overweight” rating in a research report on Wednesday, January 28th. Stifel Nicolaus lifted their target price on Johnson & Johnson from $205.00 to $220.00 and gave the company a “hold” rating in a research note on Thursday, January 22nd. Argus boosted their target price on shares of Johnson & Johnson from $210.00 to $240.00 in a report on Friday, January 23rd. Finally, Scotiabank restated an “outperform” rating on shares of Johnson & Johnson in a report on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $234.87.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.